Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
by ecancer reporter Vanessa Lane
Allogeneic stem cell transplant (allo) in patients with multiple myeloma (MM) is a controversial treatment method.
A recent study of relapsed patients after autologous stem cell transplant (ASCT) showed that those patients treated with reduced intensity conditioning allo (RIC/allo) had better progression free survival (PFS) versus those patients who received novel therapies, but that overall survival (OS) was similar.
Upfront treatment with ASCT-RIC/allo has been more promising and has showed improvements in both PFS and OS versus ASCT alone in 2 out of 6 prospective trials. One of these studies was the EBMT-NMAM2000 study, which demonstrated significant improvements in PFS and OS for ASCT-RIC/allo versus ASCT alone at 96 months (22% vs 12% and 49% vs 36%, respectively).
Future clinical studies are needed to investigate the use of ASCT-RIC/allo in combination with novel therapies to establish whether it has a place in the upfront treatment of high risk patients and those experiencing relapse.
The World Cancer Declaration recognises that to make major reductions in premature deaths, innovative education and training opportunities for healthcare workers in all disciplines of cancer control need to improve significantly.
ecancer plays a critical part in improving access to education for medical professionals.
Every day we help doctors, nurses, patients and their advocates to further their knowledge and improve the quality of care. Please make a donation to support our ongoing work.
Thank you for your support.